Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
NCT ID: NCT00326326
Last Updated: 2009-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
84 participants
INTERVENTIONAL
2006-07-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
NCT00404001
Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia
NCT00293878
Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
NCT01972178
Study of MB07811 in Subjects With Hypercholesterolemia
NCT00879112
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
NCT01058083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-778,875
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Triglycerides between 150-500 mg/dL
* Fasting Plasma Glucose 140-240 mg/dL
Exclusion Criteria
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Anniston, Alabama, United States
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Greenbrae, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
DeFuniak Springs, Florida, United States
Pfizer Investigational Site
Destin, Florida, United States
Pfizer Investigational Site
Jupiter, Florida, United States
Pfizer Investigational Site
Melbourne, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Conyers, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Springfield, Missouri, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Mount Vernon, New York, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Bryan, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Newport News, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Yakima, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5561005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.